July 02, 2012
1 min read

Aberration-optimized ablation profile addresses presbyopia

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

ROME — Supracor, an aberration-optimized algorithm for the treatment of presbyopia with the Technolas excimer workstation, shows promise in preliminary results, according to one surgeon.

Based on the experience of Intracor, the Technolas Perfect Vision intrastromal presbyopic treatment, Supracor is a tissue-saving method of multifocal photoablation, performed under a thin LASIK flap to address near vision in hyperopic presbyopes. It is no longer a monovision approach, and the same treatment profile is used in both eyes.

Roberto Bellucci

Roberto Bellucci

Roberto Bellucci, MD, has so far used this treatment in 20 eyes of 11 patients between the ages of 49 years and 64 years. One patient received monolateral treatment to correct amblyopia, and one patient received monolateral treatment to correct pseudophakic refractive error. He said at the joint Refractive.online and SICCSO meeting that his results are promising.

“Inclusion criteria are for now very strict, with refraction between +1 D and +2 D with no more than 1 D of astigmatism. [Keratometry] readings must be between 42 D and 44 D and vision 20/25 or better,” Bellucci said.

Three months after the treatment, mean sphere was –0.28 D, visual acuity was 20/25 and near vision was J2, which allowed patients to read the newspaper without spectacle correction.

“Distance vision was suboptimal for a few weeks after surgery but continued to improve, also after 3 months. At 6 months, distance vision complaints are really very few, and all patients are very satisfied with the results. However, I tell my patients that multifocality is always a compromise and that there might be a little sacrifice of distant vision,” Bellucci said.

He said that this procedure may challenge multifocal IOL implantation in the future.

Disclosure: Bellucci has no relevant financial disclosures.